Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20427395 | 1.00 | SLC29A1 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL13134626 | 1.00 | SLC29A1 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL800876 | 0.91 | POLA1 (0.44) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL10492407 | 0.89 | P2RY2 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL3952359 | 0.89 | P2RY2 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL29403438 | 0.89 | P2RY2 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL800274 | 0.89 | POLA1 (0.38) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL540156 | 0.89 | P2RY2 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL541102 | 0.89 | P2RY2 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL30256684 | 0.89 | P2RY2 (0.41) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | SLC29A1 33/4885SLC28A1 56/4885SLC28A2 64/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | SLC29A1 21/4885SLC28A1 45/4885SLC28A2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.